1887

Abstract

The 13-valent pneumococcal conjugate vaccine (PCV-13) was introduced in the United States in 2010. Using a large paediatric carriage sample collected from shortly after the introduction of PCV-7 to several years after the introduction of PCV-13, we investigate alterations in the composition of the pneumococcal population following the introduction of PCV-13, evaluating the extent to which the post-vaccination non-vaccine type (NVT) population mirrors that from prior to vaccine introduction and the effect of PCV-13 on vaccine type lineages. Draft genome assemblies from 736 newly sequenced and 616 previously published pneumococcal carriage isolates from children in Massachusetts between 2001 and 2014 were analysed. Isolates were classified into one of 22 sequence clusters (SCs) on the basis of their core genome sequence. We calculated the SC diversity for each sampling period as the probability that any two randomly drawn isolates from that period belong to different SCs. The sampling period immediately after the introduction of PCV-13 (2011) was found to have higher diversity than preceding (2007) or subsequent (2014) sampling periods {Simpson’s D 2007: 0.915 [95 % confidence interval (CI) 0.901, 0.929]; 2011:  0.935 [0.927, 0.942]; 2014 :  0.912 [0.901, 0.923]}. Amongst NVT isolates, we found the distribution of SCs in 2011 to be significantly different from that in 2007 or 2014 (Fisher’s exact test P=0.018, 0.0078), but did not find a difference comparing 2007 to 2014 (Fisher’s exact test P=0.24), indicating greater similarity between samples separated by a longer time period than between samples from closer time periods. We also found changes in the accessory gene content of the NVT population between 2007 and 2011 to have been reduced by 2014. Amongst the new serotypes targeted by PCV-13, four were present in our sample. The proportion of our sample composed of PCV-13-only vaccine serotypes 19A, 6C and 7F decreased between 2007 and 2014, but no such reduction was seen for serotype 3. We did, however, observe differences in the genetic composition of the pre- and post-PCV-13 serotype 3 population. Our isolates were collected during discrete sampling periods from a small geographical area, which may limit the generalizability of our findings. Pneumococcal diversity increased immediately following the introduction of PCV-13, but subsequently returned to pre-vaccination levels. This is reflected in the distribution of NVT lineages, and, to a lesser extent, their accessory gene frequencies. As such, there may be a period during which the population is particularly disrupted by vaccination before returning to a more stable distribution. The persistence and shifting genetic composition of serotype 3 is a concern and warrants further investigation.

Loading

Article metrics loading...

/content/journal/mgen/10.1099/mgen.0.000252
2019-02-19
2020-01-20
Loading full text...

Full text loading...

/deliver/fulltext/mgen/5/2/mgen000252.html?itemId=/content/journal/mgen/10.1099/mgen.0.000252&mimeType=html&fmt=ahah

References

  1. Mehr S, Wood N. Streptococcus pneumoniae – a review of carriage, infection, serotype replacement and vaccination. Paediatr Respir Rev 2012;2–8
    [Google Scholar]
  2. Lee GM, Kleinman K, Pelton SI, Hanage W, Huang SS et al. Impact of 13-valent pneumococcal conjugate vaccination on Streptococcus pneumoniae carriage in young children in Massachusetts. J Pediatric Infect Dis Soc 2014;3:23–32 [CrossRef][PubMed]
    [Google Scholar]
  3. Huang SS, Johnson KM, Ray GT, Wroe P, Lieu TA et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 2011;29:3398–3412 [CrossRef][PubMed]
    [Google Scholar]
  4. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737–1746 [CrossRef][PubMed]
    [Google Scholar]
  5. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201:32–41 [CrossRef][PubMed]
    [Google Scholar]
  6. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000;30:100–121 [CrossRef][PubMed]
    [Google Scholar]
  7. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D et al. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 2005;116:e408e413 [CrossRef][PubMed]
    [Google Scholar]
  8. Huang SS, Hinrichsen VL, Stevenson AE, Rifas-Shiman SL, Kleinman K et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 2009;124:e1e11 [CrossRef][PubMed]
    [Google Scholar]
  9. Moore MR, Gertz RE, Woodbury RL, Barkocy-Gallagher GA, Schaffner W et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008;197:1016–1027 [CrossRef][PubMed]
    [Google Scholar]
  10. Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007;26:468–472 [CrossRef][PubMed]
    [Google Scholar]
  11. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015;15:301–309 [CrossRef][PubMed]
    [Google Scholar]
  12. Yildirim I, Hanage WP, Lipsitch M, Shea KM, Stevenson A et al. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine 2010;29:283–288 [CrossRef][PubMed]
    [Google Scholar]
  13. Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis 2014;14:839–846 [CrossRef]
    [Google Scholar]
  14. Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014;59:1066–1073 [CrossRef][PubMed]
    [Google Scholar]
  15. Hanage WP, Finkelstein JA, Huang SS, Pelton SI, Stevenson AE et al. Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics 2010;2:80–84 [CrossRef][PubMed]
    [Google Scholar]
  16. Croucher NJ, Finkelstein JA, Pelton SI, Mitchell PK, Lee GM et al. Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet 2013;45:656–663 [CrossRef][PubMed]
    [Google Scholar]
  17. Chang Q, Stevenson AE, Croucher NJ, Lee GM, Pelton SI et al. Stability of the pneumococcal population structure in Massachusetts as PCV13 was introduced. BMC Infect Dis 2015;15:68 [CrossRef][PubMed]
    [Google Scholar]
  18. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 2012;19:455–477 [CrossRef][PubMed]
    [Google Scholar]
  19. Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics 2014;30:2068–2069 [CrossRef][PubMed]
    [Google Scholar]
  20. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S et al. Roary: rapid large-scale prokaryote pan genome analysis. Bioinformatics 2015;31:btv4213691–3693 [CrossRef][PubMed]
    [Google Scholar]
  21. Hanage WP, Bishop CJ, Huang SS, Stevenson AE, Pelton SI et al. Carried pneumococci in Massachusetts children: the contribution of clonal expansion and serotype switching. Pediatr Infect Dis J 2011;30:302–308 [CrossRef][PubMed]
    [Google Scholar]
  22. Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ et al. SRST2: Rapid genomic surveillance for public health and hospital microbiology labs. Genome Med 2014;6:90 [CrossRef][PubMed]
    [Google Scholar]
  23. Bentley SD, Aanensen DM, Mavroidi A, Saunders D, Rabbinowitsch E et al. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS Genet 2006;2:e31 [CrossRef][PubMed]
    [Google Scholar]
  24. Park IH, Park S, Hollingshead SK, Nahm MH. Genetic basis for the new pneumococcal serotype, 6C. Infect Immun 2007;75:4482–4489 [CrossRef][PubMed]
    [Google Scholar]
  25. Price MN, Dehal PS, Arkin AP. FastTree: computing large minimum evolution trees with profiles instead of a distance matrix. Mol Biol Evol 2009;26:1641–1650 [CrossRef][PubMed]
    [Google Scholar]
  26. Cheng L, Connor TR, Sirén J, Aanensen DM, Corander J. Hierarchical and spatially explicit clustering of DNA sequences with BAPS software. Mol Biol Evol 2013;30:1224–1228 [CrossRef][PubMed]
    [Google Scholar]
  27. Simpson EH. Measurement of diversity. Nature 1949;163:688 [CrossRef]
    [Google Scholar]
  28. Hanage WP, Finkelstein JA, Huang SS, Pelton SI, Stevenson AE et al. Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics 2010;2:80–84 [CrossRef][PubMed]
    [Google Scholar]
  29. Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis 2013;57:952–962 [CrossRef][PubMed]
    [Google Scholar]
  30. Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P et al. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 2011;29:7207–7211 [CrossRef][PubMed]
    [Google Scholar]
  31. Stamatakis A. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. Bioinformatics 2006;22:2688–2690 [CrossRef][PubMed]
    [Google Scholar]
  32. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J et al. The sequence alignment/Map format and SAM tools. Bioinformatics 2009;25:2078–2079 [CrossRef][PubMed]
    [Google Scholar]
  33. Hanage WP, Fraser C, Tang J, Connor TR, Corander J. Hyper-recombination, diversity, and antibiotic resistance in pneumococcus. Science 2009;324:1454–1457 [CrossRef][PubMed]
    [Google Scholar]
  34. Hanage WP, Bishop CJ, Lee GM, Lipsitch M, Stevenson A et al. Clonal replacement among 19A Streptococcus pneumoniae in Massachusetts, prior to 13 valent conjugate vaccination. Vaccine 2011;29:8877–8881 [CrossRef][PubMed]
    [Google Scholar]
  35. Corander J, Fraser C, Gutmann MU, Arnold B, Hanage WP et al. Frequency-dependent selection in vaccine-associated pneumococcal population dynamics. Nat Ecol Evol 2017;1:1950–1960 [CrossRef][PubMed]
    [Google Scholar]
  36. Park IH, Moore MR, Treanor JJ, Pelton SI, Pilishvili T et al. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 2008;198:1818–1822 [CrossRef][PubMed]
    [Google Scholar]
  37. Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC et al. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 2007;45:1225–1233 [CrossRef][PubMed]
    [Google Scholar]
  38. Azarian T, Mitchell PK, Georgieva M, Thompson CM, Ghouila A et al. Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci. PLoS Pathog 2018;14:e1007438 [CrossRef][PubMed]
    [Google Scholar]
  39. Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C et al. Genetic diversity and protective efficacy of the RTS,S/AS01 malaria vaccine. N Engl J Med 2015;373:2025–2037 [CrossRef][PubMed]
    [Google Scholar]
  40. Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012;30:B26–B36 [CrossRef][PubMed]
    [Google Scholar]
  41. Ali O, Aseffa A, Bedru A.MenAfriCar consortium The diversity of meningococcal carriage across the African meningitis belt and the impact of vaccination with a group a meningococcal conjugate vaccine. J Infect Dis 2015;212:1298–1307 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/mgen/10.1099/mgen.0.000252
Loading
/content/journal/mgen/10.1099/mgen.0.000252
Loading

Data & Media loading...

Supplements

Supplementary File 1

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error